About Philip Saylor, MD

Philip Saylor MD is a genitourinary medical oncologist and clinical/translational investigator at the MGH Cancer Center where he has been an attending physician since 2010. His in-person clinic is located on the MGH Boston campus in the Yawkey building on the 7th floor (Yawkey 7E clinic area), though he also provides virtual care. He and his team provide collaborative care for patients with genitourinary cancers (prostate, kidney/renal cell, bladder & upper tract urothelial, testicular, and adrenal cancers). His practice is primarily based in the outpatient clinic, but he also works approximately 1 month per year providing hospital-based care. 

His research is focused on prostate cancer and other genitourinary cancers with emphases on (1) team-oriented bedside-to-bench collaboration to better understand the biology of the tumor microenvironment, and (2) the metabolic side effects of systemic prostate cancer treatments. Among other efforts, he has worked since 2016 with a diverse coalition of collaborators (clinically-focused physicians, lab investigators focused on tumor biology, and a bio-informatics lab) to study human bone metastasis tissue at the single cell level. It is his belief that this sort of low ego / team-oriented research can accomplish things that wouldn't be possible for any smaller sub-set of the people involved. Improving the lives of patients is the ultimate goal of all of this work.

Dr. Saylor is originally from the San Francisco Bay Area. He earned his MD from the University of Pittsburgh School of Medicine, then completed his internal medicine residency at the University of California San Diego. His fellowship training in medical oncology was at Dana Farber Cancer Institute and MGH.

Clinical Interests:

Treats:

Locations

Hematology/Oncology
55 Fruit Street, Yawkey 7E
Boston, MA 02114
Clinic: 617-724-5197
Fax: 617-726-8685

Medical Education

  • MD, University of Pittsburgh School of Medicine
  • Residency, UC San Diego Medical Center
  • Residency, UCSD Medical Center
  • Fellowship, Dana Farber Cancer Institute
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Medical Oncology, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Publications

  • View my most recent publications at PubMed

    Selected Publications:

    • Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, Kungel TM, Nissenberg MG, Michalski JM. Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. J Clin Oncol. 2020 May 20;38(15):1736-1743. PMID: 31990618.

    • Amorim BJ, Prabhu V, Marco SS, Gervais D, Palmer WE, Heidari P, Vangel M, Saylor PJ, Catalano OA. Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):105-114. PMID: 31492992.

    • Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, et al. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Dec;17(12):1529-1554. PMID: 31805523.

    • Saylor PJ, Lee RJ, Arora KS, Deshpande V, Hu R, Olivier K, Meneely E, Rivera MN, Ting DT, Wu CL, Miyamoto DT. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res. 2017 Jan 15;23(2):363-369. PMID: 27440270.

    • Singh H, Liu Y, Xiao X, Lin L, Kim J, Van Hummelen P, Wu CL, Bass AJ, Saylor PJ. Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. Oncotarget. 2016 May 17;7(20):29211-5. PMID: 27078850.